Head-To-Head Comparison: Antares Pharma (ATRS) & Invivo Therapeutics (NASDAQ:NVIV)

Antares Pharma (NASDAQ:ATRS) and Invivo Therapeutics (NASDAQ:NVIV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a breakdown of current ratings and price targets for Antares Pharma and Invivo Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Antares Pharma 0 0 4 1 3.20
Invivo Therapeutics 0 0 0 0 N/A

Antares Pharma presently has a consensus target price of $4.83, indicating a potential upside of 71.81%. Given Antares Pharma’s higher probable upside, research analysts plainly believe Antares Pharma is more favorable than Invivo Therapeutics.

Valuation & Earnings

This table compares Antares Pharma and Invivo Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Antares Pharma $63.55 million 7.19 -$6.51 million ($0.04) -70.25
Invivo Therapeutics N/A N/A -$23.42 million ($2.25) -0.50

Antares Pharma has higher revenue and earnings than Invivo Therapeutics. Antares Pharma is trading at a lower price-to-earnings ratio than Invivo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

40.7% of Antares Pharma shares are held by institutional investors. Comparatively, 8.1% of Invivo Therapeutics shares are held by institutional investors. 5.5% of Antares Pharma shares are held by company insiders. Comparatively, 0.3% of Invivo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Antares Pharma and Invivo Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Antares Pharma -7.91% -17.94% -6.99%
Invivo Therapeutics N/A -184.17% -105.56%

Risk and Volatility

Antares Pharma has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Invivo Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500.

Summary

Antares Pharma beats Invivo Therapeutics on 10 of the 13 factors compared between the two stocks.

Antares Pharma Company Profile

Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.

Invivo Therapeutics Company Profile

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.